Medicilon Congratulates AI-Driven Biotech Insilico Medicine on Its HKEX Debut in Hong Kong’s Largest Biotech IPO of 2025
On December 30, Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence, successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 3696.HK). The offering raised HK$2.277 billion, making it the largest biotech IPO in Hong Kong in 2025 and the first AI-driven biotech company to list under Listing […]
Boston Non-Tumor Models Innovation
Learn more about our Non Tumor Model 1. Imiquimod (IMQ) Induced Psoriasis model Imiquimod (IMQ) Induced Psoriasis model. Female Balb/c mice (9 weeks old) were treated topically with imiquimod (IMQ) on the ear and dorsal skin for seven consecutive days (A). Psoriasis Area and Severity Index (PASI) (B), dorsal skin thickness change (%) (C), and […]
Efficient Collaboration Earns High Praise: RayThera Honors Medicilon with “Excellent Partnership Award”
On November 10, Dr. Gene Hung, Founder and Chief Scientific Officer of RayThera, Inc., visited Medicilon’s Nanhui campus to further strengthen strategic collaboration and recognize outstanding achievements. During the visit, RayThera presented Medicilon with the “Excellent Partnership Award”, the Chemistry FTE Team with the “Excellent Service Team Award”, and Dr. Zhu Du, Vice President of […]
Medicilon | Featured Sponsor for ACCESS ASIA BD Forum @ JPM 2026
January 11, 2026 | InterContinental San Francisco In a world where biotech innovation thrives on collaboration, Medicilon as the Featured Sponsor for the ACCESS ASIA BD Forum @ JPM 2026. Our Mission: Your Partner from Concept to IND As a global leader in integrated preclinical research services, Medicilon has long been the bridge between discovery […]
Advancing a New Paradigm in Drug Development: Medicilon and Xellar Biosystems Forge a Strategic Partnership
Shanghai, November 6, 2025 – At the 8th China International Import Expo, Medicilon officially signed a strategic cooperation agreement with Xellar Biosystems, a biotech company pioneering the integration of organ-on-a-chip and AI technologies. This partnership combines Medicilon’s one-stop preclinical drug R&D service platform with Xellar’s advanced organ-on-a-chip systems, AI analytics, and high-content 3D imaging to […]
Medicilon Earns OECD GLP Certification from Hungary, Strengthening Global Compliance Network
Shanghai, China – October 9, 2025 – Medicilon is proud to announce that it has officially obtained certification of compliance with OECD Good Laboratory Practice (GLP) standards from Hungary, a member country of the Organization for Economic Co-operation and Development (OECD). This achievement marks another important milestone in Medicilon’s continuous pursuit of international quality excellence, […]
Medicilon Empowers Strategic Partner SAPU to Obtain Clinical Trial Approval for Sapu003 in Australia
Recently, Sapu003, an innovative drug developed by SAPU Bioscience, has officially obtained clinical trial approval in Australia. This is the first successfully approved IND since Medicilon and SAPU entered into a strategic agreement for 20 IND projects in February this year. The quality and speed of this approval serve as a strong testament to the […]
Medicilon Receives International Accreditation Again! Successfully Obtains OECD GLP Certificate
Recently, Medicilon has officially obtained the Good Laboratory Practice (GLP) certificate issued by Mexico, a member country of the Organization for Economic Co-operation and Development (OECD). Medicilon also has passed the GLP on-site inspections conducted by Hungary, another member country of the OECD. Following the recent FDA and PMDA GLP audit , this success further […]
【White Paper】Navigating the DMPK Gauntlet: A Strategic Analysis of the Interconnected Challenges Shaping the Future of Drug Development
1.0 Executive Summary & Introduction The Drug Metabolism and Pharmacokinetics (DMPK) landscape is at a critical inflection point, shaped by the convergence of four powerful and interconnected forces: scientific complexity, technological disruption, regulatory and geopolitical upheaval, and intense business pressures. The traditional paradigms that once guided preclinical development are no longer sufficient. The rise of […]
Medicilon: Innovating Globally at CMC-China Expo 2025
CMC-China Expo 2025 August 1, 2025–The CMC-China Expo 2025, themed “Breakthrough, Symbiosis, and Globalization,” opened today at the Suzhou International Expo Centre. The conference gathers biopharmaceutical experts and executives to foster collaboration on innovative technologies and explore future industry development, addressing key topics to drive high-quality growth in the biopharmaceutical sector. Top 20 Preclinical CROs […]
